Liposomal-encapsulated doxorubicin supercharge-containing front-line treatment improves response rates in primary mediastinal large B-cell lymphoma and mediastinal gray zone lymphoma

Hematol Oncol. 2024 Jan;42(1):e3242. doi: 10.1002/hon.3242. Epub 2023 Dec 21.

Authors

M Picardi¹, C Giordano¹, N Pugliese¹, M Mascolo², S Varricchio², G Troncone³, E Vigliar³, C Bellavicine³, M Lamagna¹, D Lisi¹, A Vincenzi¹, F Pane¹

Affiliations

¹ Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy.
² Department of Advanced Biomedical Sciences, Federico II University Medical School, Naples, Italy.
³ Department of Public Health, Federico II University Medical School Naples, Naples, Italy.

PMID: 38126215
DOI: 10.1002/hon.3242

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Doxorubicin / therapeutic use
Humans
Lymphoma, B-Cell* / pathology
Lymphoma, Large B-Cell, Diffuse* / drug therapy
Lymphoma, Large B-Cell, Diffuse* / pathology
Mediastinal Neoplasms* / pathology
Polyethylene Glycols / therapeutic use

Substances

liposomal doxorubicin
Doxorubicin
Polyethylene Glycols